Skip to main content
Caplight Logo









ClotProtect Therapeutics

ClotProtect Therapeutics

Private
LeedsHealthcare & Life Scienceshttps://www.clotprotect.com/

Last Round

Seed

Feb 18, 2026

Total Funding Raised

$1.62M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

ClotProtect Therapeutics is a biotechnology company that develops small molecule anti-fibrinolytic agents for the treatment of acute hemorrhage and traumatic bleeding.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverythrombosisanticoagulantblood clot treatmentpreclinical researchsmall-molecule drugbiotech startuppharma R&Dtherapeutic candidateantithromboticdrug pipelinebiotech spin-out

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ClotProtect Therapeutics Comparables

Compare ClotProtect Therapeutics with similar companies based on industry and business-model similarity.

ClotProtect Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Lunac Therapeutics
88%
Coagulant Therapeutics Corporation
54%
Cayuga Biotech
53%

ClotProtect Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedFeb 18, 2026
Pre SeedApr 22, 2024

ClotProtect Therapeutics Investors

Notable investors and investment history

ClotProtect Therapeutics investors
InvestorRounds
University of LeedsPre Seed
Lifted VenturesSeed
o2h venturesPre Seed
Innovate UKSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 18, 2026

    $1.6M round led by Lifted Ventures.

  • Apr 22, 2024

    Led by o2h ventures with participation from University of Leeds.

ClotProtect Therapeutics Filings

Explore SEC and related filing metadata, where available.

ClotProtect Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ClotProtect Therapeutics's valuation, stock price, and market status.

Is ClotProtect Therapeutics a public or private company?

ClotProtect Therapeutics is a private company.

What is the current stock price of ClotProtect Therapeutics?

ClotProtect Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is ClotProtect Therapeutics worth (valuation)?

Valuation information for ClotProtect Therapeutics is not publicly available.

Can I buy ClotProtect Therapeutics stock?

ClotProtect Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ClotProtect Therapeutics's last funding round?

ClotProtect Therapeutics's most recent funding round was Seed on February 18, 2026.

Who are the main investors in ClotProtect Therapeutics?

Key investors in ClotProtect Therapeutics include Lifted Ventures, o2h ventures.

Will ClotProtect Therapeutics IPO soon?

No public IPO plans have been announced for ClotProtect Therapeutics.

How can I track ClotProtect Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ClotProtect Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLeeds
Year Founded2024
Last FundingFeb 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?